# Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

> **NCT04657679** · PHASE4 · TERMINATED · sponsor: **Georgetown University** · enrollment: 21 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT04657679
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-20
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Sufficient accrual into the African American/Black patient cohort and insufficient accrual into the NHW patient cohort.
- **Last updated:** 2024-11-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657679, "Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04657679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*